Human Monoclonal Antibodies Against Hendra and Nipah Viruses

Abstract

The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

1 . A substantially pure polypeptide comprising an antibody selectively binding a Hendra or Nipah G glycoprotein epitope, wherein said antibody includes a heavy chain CDR3 region having the amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 39, SEQ ID NO: 55, SEQ ID NO: 71, SEQ ID NO: 87, SEQ ID NO: 103, SEQ ID NO: 119, SEQ ID NO: 135, SEQ ID NO: 151, SEQ ID NO: 167, SEQ ID NO: 183, SEQ ID NO: 199, SEQ ID NO: 215, SEQ ID NO: 231, SEQ ID NO: 247, SEQ ID NO: 263, SEQ ID NO: 279, SEQ ID NO: 295, SEQ ID NO: 311, SEQ ID NO: 327, SEQ ID NO: 343, SEQ ID NO: 359, SEQ ID NO: 375, SEQ ID NO: 391 and SEQ ID NO: 407. 
     
     
         2 . The substantially pure polypeptide of  claim 1  wherein said antibody comprises an Fd fragment. 
     
     
         3 . The substantially pure polypeptide of  claim 1  wherein said antibody comprises an Fab fragment. 
     
     
         4 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain CDR2 region having the amino acid sequence of:
 a) SEQ ID NO: 5 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 21 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 37 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 53 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 69 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 85 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 101 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 117 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 133 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 149 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 165 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 181 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 197 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 213 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 229 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 245 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 261 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 277 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 293 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 309 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 325 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 341 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 357 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 373 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 389 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 405 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         5 . The substantially pure polypeptide of  claim 4  wherein said antibody includes a heavy chain CDR1 region having the amino acid sequence of:
 a) SEQ ID NO: 3 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 19 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 35 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 51 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 67 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 83 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 99 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 115 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 131 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 147 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 163 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 179 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 195 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 211 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 227 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 243 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 259 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 275 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 291 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 307 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 323 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 339 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 355 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 371 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 387 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 403 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         6 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain Fd region including the amino acid sequence of:
 a) SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 49 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 65 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 81 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 97 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 113 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 129 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 161 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 177 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 193 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 209 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 225 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 241 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 257 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 273 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 289 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 305 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 321 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 337 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 353 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 369 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 385 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 401 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         7 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a light chain CDR3 region having the amino acid sequence of:
 a) SEQ ID NO: 15 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 31 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 47 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 63 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 79 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 95 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 111 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 127 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 143 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 159 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 175 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 191 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 207 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 223 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 239 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 255 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 271 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 287 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 303 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 319 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 335 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 351 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 367 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 383 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 399 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 415 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         8 . The substantially pure polypeptide of  claim 7  wherein said antibody includes a light chain CDR2 region having the amino acid sequence of:
 a) SEQ ID NO: 13 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 29 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 45 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 61 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 77 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 93 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 109 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 125 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 141 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 157 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 173 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 189 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 205 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 221 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 237 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 253 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 269 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 285 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 301 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 317 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 333 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 349 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 365 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 381 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 397 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 413 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         9 . The substantially pure polypeptide of  claim 8  wherein said antibody includes a light chain CDR1 region having the amino acid sequence of:
 a) SEQ ID NO: 11 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 27 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 43 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 59 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 75 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 91 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 107 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 123 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 139 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 155 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 171 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 187 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 203 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 219 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 235 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 251 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 267 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 283 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 299 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 315 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 331 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 347 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 363 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 379 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 395 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 411 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         10 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a light chain region including the amino acid sequence of:
 a) SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 25 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 41 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 73 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 89 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 105 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 121 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 153 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 169 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 185 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 201 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 217 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 233 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 249 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 265 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 281 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 297 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 313 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 329 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 345 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 361 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 377 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 393 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 409 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         11 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain Fd region including the CDR amino acid sequences of:
 a) SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 49 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 65 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 81 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 97 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 113 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 129 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 161 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 177 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 193 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 209 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 225 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 241 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 257 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 273 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 289 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 305 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 321 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 337 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 353 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 369 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 385 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 401 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         12 . The substantially pure polypeptide of  claim 11  wherein said antibody includes a light chain region including the CDR amino acid sequences of:
 a) SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 25 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 41 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 73 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 89 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 105 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 121 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 153 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 169 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 185 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 201 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 217 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 233 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 249 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 265 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 281 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 297 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 313 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 329 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 345 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 361 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 377 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 393 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 409 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         13 . An isolated nucleic acid comprising a nucleotide sequence encoding the substantially pure polypeptide of  claim 1 . 
     
     
         14 . An isolated nucleic acid as in  claim 13  wherein said nucleic acid comprises a vector including a regulatory sequence operably joined to said nucleic acid. 
     
     
         15 . A host cell including a vector comprising a nucleic acid of  claim 13 . 
     
     
         16 . A pharmaceutical preparation comprising a pharmaceutically acceptable carrier; and the substantially pure polypeptide of  claim 1 . 
     
     
         17 . A diagnostic preparation comprising a pharmaceutically acceptable carrier; and the substantially pure polypeptide of  claim 1 . 
     
     
         18 . A method for the treatment of Hendra Virus Disease or Nipah Virus Disease comprising administering to a patient a therapeutically effective amount of the pharmaceutical preparation of  claim 16 . 
     
     
         19 . A method for prophylaxis against Hendra Virus Disease or Nipah Virus Disease comprising administering to a patient a prophylactically effective amount of the pharmaceutical preparation of  claim 16 . 
     
     
         20 . A method for the diagnosis of Hendra Virus Disease or Nipah Virus Disease comprising administering to a patient an effective amount of the diagnostic preparation of  claim 17 , and detecting binding of the substantially pure polypeptide as a determination of the presence of Hendra Virus Disease or Nipah Virus Disease. 
     
     
         21 . A method of detecting the presence of Hendra or Nipah virus in a biological sample comprising contacting said sample with the diagnostic preparation of  claim 17 , and assaying binding of the substantially pure polypeptide as a determination of the presence of said Hendra or Nipah virus. 
     
     
         22 . A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which an antibody selectively binding a Hendra or Nipah G glycoprotein epitope binds, wherein said antibody includes a heavy chain CDR3 region having the amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 39, SEQ ID NO: 55, SEQ ID NO: 71, SEQ ID NO: 87, SEQ ID NO: 103, SEQ ID NO: 119, SEQ ID NO: 135, SEQ ID NO: 151, SEQ ID NO: 167, SEQ ID NO: 183, SEQ ID NO: 199, SEQ ID NO: 215, SEQ ID NO: 231, SEQ ID NO: 247, SEQ ID NO: 263, SEQ ID NO: 279, SEQ ID NO: 295, SEQ ID NO: 311, SEQ ID NO: 327, SEQ ID NO: 343, SEQ ID NO: 359, SEQ ID NO: 375, SEQ ID NO: 391 and SEQ ID NO: 407.